MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Age-associated changes in the striatal proteins in aging Asian-Indians

    H J. Jyothi, A. Mahadevan, T C. Yasha, P. Alladi (Bengaluru, India)

    Objective: To examine the age-related changes in tyrosine hydroxylase (TH), vesicular monoamine transporter2 (VMAT2), post-synaptic density protein-95 (PSD-95) and dopamine receptors (D1R, D2R) expression in the…
  • 2023 International Congress

    An evaluation of NBI-827104 for essential tremor: results from a randomized, double-blind, placebo-controlled, dose-escalation, crossover study

    C. de Cuba, L. Smits, P. Kremer, R-J. Doll, J. Heuberger, R. Helmich, A F. van Rootselaar, R. Elble, W. Ondo, L. Rees, N. Wedick, G. Liang, D. Haubenberger (Leiden, Netherlands)

    Objective: To evaluate the efficacy of NBI-827104 in patients with essential tremor (ET). Background: NBI-827104 is a T-type calcium channel blocker that demonstrated tremorolytic activity…
  • 2023 International Congress

    Clinical Prediction of GBA Carrier Status in Parkinson’s Disease

    J. Greenberg, K. Astudillo, S. Frucht, A. Flinker, G. Riboldi (New York, USA)

    Objective: To design a model for prediction of GBA carrier status based on clinical and demographic features in a cohort of PD patients. Background: Given…
  • 2023 International Congress

    Bilateral Globus Pallidus Internus Deep Brain Stimulation for Cervical Dystonia: Effects on Motor and Non-Motor Symptoms within 5 Years Follow Up

    A. Khanom, P. Franceschini, S. Lane, J. Osman-Farah, A. Macerollo (Liverpool, United Kingdom)

    Objective: This study firstly aims to measure the efficacy of GPi-DBS on motor and non-motor symptoms of CD. A secondary aim was to evaluate if…
  • 2023 International Congress

    using latent class mixed modelling to profile Parkinson’s disease patients at risk of cognitive decline

    D. Pourzinal, R. Lawson, A. Yarnall, D. Burn, C. Williams-Gray, R. Barker, J. Yang, K. Mcmahon, J. O'Sullivan, G. Byrne, N. Dissanayaka (Herston, Australia)

    Objective: To determine the clinical profile of cognitive subtypes in Parkinson's disease (PD) based on their rate of change in global cognitive ability over time.…
  • 2023 International Congress

    Effects of motor and cognitive complex training on obstacle-crossing ability in participants with Parkinson’s disease

    R Y. Wang, C W. Hung, Y R. Yang (Taipei, Taiwan)

    Objective: To investigate the effects of complex walking training and motor-cognitive training on obstacle-crossing ability in Parkinson’s disease (PD). Background: Obstacle crossing needs both motor…
  • 2023 International Congress

    Mobile and electronic health-supported physical activity in Parkinson’s disease: A scoping review

    M. Bopp, J. Krell-Roesch, Y. Geda, S. Aslam, A. Woll (Karlsruhe, Germany)

    Objective: To conduct an overview of current research on mobile and electronic (m- and e-) health-supported physical activity (PA) programs in persons with Parkinson’s disease…
  • 2023 International Congress

    Assessing non-motor symptoms and associations with quality of life among patients in Korle-Bu Teaching Hospital, Ghana

    D. Brodie-Mends, F. Duodu, K. Nkromah, A. Akpalu (Accra, Ghana)

    Objective: To determine the prevalence and types of non-motor symptoms (NMS) and their relation to quality of life among Parkinson’s disease (PD) patients who attend…
  • 2023 International Congress

    Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial

    O. Rascol, F. Ory-Magne, JP. Azulay, L. Defebvre, JL. Houeto, D. Maltete, P. Remy, A. Foubert-Samier, A. Sommet, C. Thalamas, S. Thobois, JC. Corvol, N. Ns-Park/fcrin (Toulouse, France)

    Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…
  • 2023 International Congress

    Progressive cortical cerebrovascular reactivity reduction occurs in Parkinson’s disease: a longitudinal study

    LR. Jin (Shanghai, China)

    Objective: In the longitudinal study, we aimed to investigate regional cerebrovascular reactivity (CVR) changes in the patients with PD at baseline and during a 2-year…
  • « Previous Page
  • 1
  • …
  • 69
  • 70
  • 71
  • 72
  • 73
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley